These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 30039454

  • 1. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M.
    J Thromb Thrombolysis; 2018 Oct; 46(3):393-398. PubMed ID: 30039454
    [Abstract] [Full Text] [Related]

  • 2. First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans.
    Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M.
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):914-919. PubMed ID: 29050502
    [Abstract] [Full Text] [Related]

  • 3. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 4. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, Deisenhofer I, Hyseni A, Roest M, Ott I.
    J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M.
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [Abstract] [Full Text] [Related]

  • 6. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
    Škorňová I, Samoš M, Bolek T, Stančiaková L, Vádelová Ľ, Galajda P, Staško J, Kubisz P, Mokáň M.
    Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
    [Abstract] [Full Text] [Related]

  • 7. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
    Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M.
    Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
    [Abstract] [Full Text] [Related]

  • 8. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
    Bánovčin P, Škorňová I, Samoš M, Schnierer M, Bolek T, Kovář F, Staško J, Kubisz P, Mokáň M.
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
    [Abstract] [Full Text] [Related]

  • 9. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND.
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC, White A, Luettgen J.
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
    Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O.
    J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
    [Abstract] [Full Text] [Related]

  • 12. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
    Gay J, Duchemin J, Imarazene M, Fontenay M, Jourdi G.
    Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
    [Abstract] [Full Text] [Related]

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 14. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G, Maguire A.
    PLoS One; 2017 Apr; 12(10):e0185642. PubMed ID: 29016695
    [Abstract] [Full Text] [Related]

  • 15. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 16. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB, Fogerty AE.
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [Abstract] [Full Text] [Related]

  • 17. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR, Talbot K, Hur WS, Meixner SC, Van Der Gugten JG, Holmes DT, Côté HCF, Kastrup CJ, Smith TW, Lee AYY, Pryzdial ELG.
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [Abstract] [Full Text] [Related]

  • 18. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ, Ellekjær H, Selmer R, Ariansen I, Furu K, Skovlund E.
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [Abstract] [Full Text] [Related]

  • 19. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.
    Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED.
    Curr Med Res Opin; 2017 Jun; 33(6):1033-1043. PubMed ID: 28366075
    [Abstract] [Full Text] [Related]

  • 20. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.